Why Turning the Drug Regulator Into a Patent Gatekeeper Is a Bad Idea

Professor Emeritus Brook Baker authors an opinion piece in The Edge Malaysia warning that a proposed Malaysian drug regulatory guideline on patent linkage for pharmaceuticals goes well beyond what trade agreements require — and risks replicating the anti-competitive practices that have driven up drug costs in the United States.